This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Spectrum Pharmaceuticals, Inc.
Drug Names(s): D-63153, SPI-153
Description: D-63153 is a peptide-based active Luteinizing Hormone Releasing Hormone (LHRH) antagonist.
Deal Structure: In August 2004, AEterna Zentaris granted to Spectrum Pharmaceuticals an exclusive license to develop and market D-63153 for all potential indications in North America (including Canada and Mexico) and India. AEterna Zentaris received an upfront payment which included cash and equity of Spectrum, at signature, and is eligible to receive payments upon achievement of certain development and regulatory milestones, in addition to royalties on potential net sales. AEterna Zentaris retains exclusive rights to the rest of world and will share with Spectrum upfront and milestone payments, royalties or profits from potential sales in Japan.
In August 2006, AEterna Zentaris entered into a licensing and collaboration agreement with Nippon Kayaku for ozarelix. Under the terms of the agreement, AEterna Zentaris granted Nippon Kayaku an exclusive license to develop and market ozarelix for all potential oncological indications in Japan. In return, AEterna Zentaris is to receive an upfront...See full deal structure in Biomedtracker
Partners: AEterna Zentaris, Inc. Nippon Kayaku Co., Ltd.
Additional information available to subscribers only: